Articles Vol. 67 No. 9 25/09/2026

THE ROLE OF THYROID HORMONES IN REGULATING LIPID METABOLISM AND ENERGY BALANCE: A NARRATIVE REVIEW

Duong Kim Hon, Ton That Hung Binh, Phan Thanh Tai, Nguyen Kim Vuong
DOI: 10.52163/yhc.v67i9.6754
22 Views
0 Downloads
Abstract

Objective: To synthesize mechanistic and clinical evidence clarifying the role of thyroid hormones in regulating lipid metabolism and energy balance. The review also evaluates the current therapeutic value and future prospects of selective thyroid hormone receptor agonists.

Methods: A structured narrative review was conducted through a PubMed/MEDLINE search covering 2000–2025. The review focused on keywords related to thyroid hormone receptors (TR), deiodinases, and thyromimetics. Treatment guidelines, randomized controlled trials (RCTs), and systematic reviews addressing lipid and energy metabolism in adults were prioritized for analysis.

Results: Thyroid hormones regulate tissue-specific metabolism through differential receptor distribution, particularly TRβ in the liver, and through local deiodinase activity. In the liver, TRβ signaling promotes LDL clearance and fatty acid oxidation. In adipose tissue, the interaction between DIO2 and sympathetic signaling helps activate thermogenesis. Clinically, overt hypothyroidism is associated with increased LDL-C and triglycerides, which often improve after levothyroxine therapy. Notably, TRβ-selective agonists are emerging as a potential therapeutic option for dyslipidemia.

Conclusion: Thyroid hormones are central regulators of whole-body lipid metabolism and energy balance. Thyroid dysfunction should be considered in the evaluation of dyslipidemia. TRβ-targeted strategies are promising therapeutic approaches, but further long-term safety data are still needed.

References
[1]
[1] Brent GA. Mechanisms of thyroid hormone action. J Clin Invest. 2012;122(9):3035-3043. doi:10.1172/JCI60047. Google Scholar
[2]
[2] Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;116(10):2571-2579. doi:10.1172/JCI29812. Google Scholar
[3]
[3] Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev. 2014;94(2):355-382. doi:10.1152/physrev.00030.2013. Google Scholar
[4]
[4] Sinha RA, Singh BK, Yen PM. Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism. Trends Endocrinol Metab. 2014;25(10):538-545. doi:10.1016/j.tem.2014.07.001. Google Scholar
[5]
[5] Duntas LH, Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am. 2012;96(2):269-281. doi:10.1016/j.mcna.2012.01.012. Google Scholar
[6]
[6] Pearce SHS, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, Wemeau JL. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J. 2013;2(4):215-228. doi:10.1159/000356507. Google Scholar
[7]
[7] Li X, Wang Y, Guan Q, Zhao J, Gao L. The lipid-lowering effect of levothyroxine in patients with subclinical hypothyroidism: a systematic review and meta-analysis of randomized controlled trials. Clin Endocrinol (Oxf). 2017;87(1):1-9. doi:10.1111/cen.13338. Google Scholar
[8]
[8] Berkenstam A, Kristensen J, Mellstrom K, Carlsson B, Malm J, Rehnmark S, et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci U S A. 2008;105(2):663-667. doi:10.1073/pnas.0705286104. Google Scholar
[9]
[9] Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010;362(10):906-916. doi:10.1056/NEJMoa0905633. Google Scholar
[10]
[10] Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394(10213):2012-2024. doi:10.1016/S0140-6736(19)32517-6. Google Scholar